CATALENT, INC. (NYSE:CTLT) Files An 8-K Results of Operations and Financial Condition

CATALENT, INC. (NYSE:CTLT) Files An 8-K Results of Operations and Financial Condition
Item 2.02Results of Operations and Financial Condition.

Story continues below

On February5, 2019, Catalent, Inc. (the “Company”) issued an earnings release setting forth the Company’s second quarter ended December31, 2018 financial results. The earnings release is furnished as Exhibit99.1 hereto and is incorporated herein by reference.

As provided in General Instruction B.2 of Form8-K, Exhibit 99.1 and the information contained in this Item 2.02 of this Form8-K shall not be deemed to be “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall they be deemed to be incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

a.Exhibits. The following Exhibits are filed (or, in the case of Exhibit 99.1, furnished) as part of this Current Report on Form 8-K.

Exhibit No. Description

99.1

Earnings release, February 5, 2019, issued by Catalent, Inc.

Catalent, Inc. Exhibit
EX-99.1 2 earningsreleaseex991-f.htm EXHIBIT 99.1 DocumentExhibit 99.1Earnings Release  Investor Contact:Catalent,…
To view the full exhibit click here

About CATALENT, INC. (NYSE:CTLT)

Catalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels. The Drug Delivery Solutions segment is engaged in the formulation, development and manufacturing of prescription and consumer and animal health products; blow-fill seal unit dose manufacturing; biologic cell line development; analytical and bioanalytical development, and testing services. The Clinical Supply Services segment is engaged in manufacturing, packaging, labeling, storage, distribution and inventory management for clinical trials of drugs and biologics for patient kits; FastChain clinical supply service; clinical e-solutions and informatics, and global comparator sourcing services.

An ad to help with our costs